CoChat

Cohort Profile: The Fremantle Diabetes Study

Open access
Davis, Timothy ME, Bruce, David G, Davis, Wendy A · 2013 · International Journal of Epidemiology
Cited by 136

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

When the Fremantle Diabetes Study (FDS) Phase I was conceived in 1991 by its chief investigator (T.M.E.D.), there were few published longitudinal community-based diabetes natural history studies. Population studies such as Framingham1 in the United States and Busselton2 in Australia contained relatively small subgroups from which limited additional diabetes-specific information was collected. The United Kingdom Prospective Diabetes Study (UKPDS) had recruited more than 5000 newly diagnosed type 2 subjects aged 25–65 years but the sample, although relatively large, was not community based. The diagnosis of diabetes was based on a low fasting plasma glucose concentration (>6 mmol/l), and the study was interventional with outcomes presented in 1998.3 There were also Australia-specific aspects of diabetes that had not been characterized in detail, especially the disproportionately large number of patients from a migrant (especially Southern European) background4 and the important question of diabetes in indigenous groups.5 The aim of FDS Phase I was, therefore, to identify from all potential sources, and collect detailed prospective data from, known diabetic patients in a stable multi-ethnic urban Australian population to examine clinically relevant aspects of diabetes including clinical management, metabolic control, complications and cost. Based on the amount of available seeding funding from the Raine Foundation, University of Western Australia (WA) and respecting a reasonable patient time commitment and throughput, it was decided to attempt to recruit all consenting patients from the Fremantle Hospital (FH) primary catchment area, a postcode-defined population of approximately 120 000 living in and around the port of Fremantle in Western Australia. A 3-year registration period between 1993 and 1996 was followed by yearly reviews of the FDS Phase I cohort until 2001 (a minimum follow-up of 5 years) by which time more than half of the patients had died or withdrawn, although acquisition of hospitalizations, cancer registrations and deaths through the WA Data Linkage System (WADLS)6 has continued since. During and after the active data collection in Phase I, the results of a number of studies were published that provided important data relating to diabetes epidemiology and management. The Australian Diabetes, Obesity, and Lifestyle (AusDiab) Study7 showed that the prevalence of diabetes had increased at the rate of 0.15%/year in males and 0.18%/year in females in individuals aged ≥25 years during the 19 years since the first Australian estimate from the Busselton survey in 1981.2 The incidence of type 1 diabetes in Australia was also increasing.8 A contributor to this increased prevalence was the lowering of the threshold fasting plasma glucose for diagnosis of diabetes from 7.8 mmol/l to 7.0 mmol/l by the World Health Organization in 1999.9 In relation to management, results of the Diabetes Control and Complications Trial (DCCT) in type 1 diabetes were first presented in 1993 and confirmed the benefits of tight glycaemic control in the prevention of microvascular disease.10 Parallel findings for type 2 diabetes from the UKPDS followed in 19983,11 but the UKPDS also highlighted the vascular benefits of intensive management of hypertension.12 Other landmark non-glycaemic intervention trials, such as the Heart Outcomes Prevention Evaluation (HOPE and MICRO-HOPE),13 the Heart Protection Study14 and the Fenofibrate Intervention and Event Lowering in Diabetes Study15 provided further evidence of the benefits of individual intensive vascular risk factor management in type 2 diabetes. The Steno-2 Study extended these findings in a multifactorial intervention that reduced both micro- and macrovascular disease.16 In addition, the 33% 2-year mortality rate in conventionally treated diabetic patients after myocardial infarction in the Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study carried out in the early 1990s17 had fallen to 19% in similar patients in the more recent DIGAMI-2 Study18 in the presence of increased use of aspirin, β-blockers, ACEI and especially statin therapy. These studies were likely to have influenced changes in management of Australian diabetic patients during and after the active data collection in Phase I. Although findings from Phase I had contributed to an understanding of the natural history of diabetes, the changes in diabetes epidemiology and management justified a Phase II that duplicated and extended data collection. Funding for this new study was obtained from the National Health and Medical Research Council of Australia and it started in the first part of 2008, some 15 years after the first patient was recruited to Phase I. The Phase II baseline cohort was recruited over a 3-year period from the same catchment area using similar methods of ascertainment as Phase I. Longitudinal follow-up data collection is continuing at present. The samples for Ph

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ije/dys065

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Metadata

Authors
Davis, T. M., Bruce, D. G., & Davis, W. A.
Venue
International Journal of Epidemiology
Published
2012-04-28
Volume
42
Issue
2
Pages
412-421
ISSN
  • 0300-5771 (ISSN-L)
  • 1464-3685
OpenAlex
W2115079411
Cited by
136
References
15
FWCI
6.90
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cohort Profile: The Fremantle Diabetes Study. https://app.cochat.ai/papers/10.1093/ije/dys065
The paper
Davis, T. M., Bruce, D. G., & Davis, W. A. (2013). Cohort Profile: The Fremantle Diabetes Study. International Journal of Epidemiology. https://doi.org/10.1093/ije/dys065

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.